{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:16:57Z","timestamp":1784233017165,"version":"3.55.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.2967\/jnumed.123.265970","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:05:19Z","timestamp":1695920719000},"page":"1918-1924","source":"Crossref","is-referenced-by-count":12,"title":["An Intrapatient Dosimetry Comparison of<sup>177<\/sup>Lu-rhPSMA-10.1 and<sup>177<\/sup>Lu-PSMA-I&amp;T in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"64","author":[{"given":"Andreas","family":"Rinscheid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"G\u00e4ble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgine","family":"Wienand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pfob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Weckermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2023120108101139000_64.12.1918.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023120108101139000_64.12.1918.2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2023120108101139000_64.12.1918.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262671"},{"key":"2023120108101139000_64.12.1918.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023120108101139000_64.12.1918.5","doi-asserted-by":"crossref","unstructured":"Hennrich U Eder M . [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15:1292.","DOI":"10.3390\/ph15101292"},{"key":"2023120108101139000_64.12.1918.6","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e31823926e5"},{"key":"2023120108101139000_64.12.1918.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2023120108101139000_64.12.1918.8","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy [abstract]","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol."},{"key":"2023120108101139000_64.12.1918.9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023120108101139000_64.12.1918.10","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.clgc.2017.08.011","article-title":"Comparison of surgery and radiation as local treatments in the risk of locoregional complications in men subsequently dying from prostate cancer","volume":"16","author":"Hu","year":"2018","journal-title":"Clin Genitourin Cancer."},{"key":"2023120108101139000_64.12.1918.11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s10147-016-0993-x","article-title":"High incidence of urological complications in men dying from prostate cancer","volume":"21","author":"Kobayashi","year":"2016","journal-title":"Int J Clin Oncol."},{"key":"2023120108101139000_64.12.1918.12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/jpm.2006.0185","article-title":"Complications arising in the final year of life in men dying from advanced prostate cancer","volume":"10","author":"Khafagy","year":"2007","journal-title":"J Palliat Med."},{"key":"2023120108101139000_64.12.1918.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178483"},{"key":"2023120108101139000_64.12.1918.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234922"},{"key":"2023120108101139000_64.12.1918.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.009"},{"key":"2023120108101139000_64.12.1918.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260091"},{"key":"2023120108101139000_64.12.1918.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.254516"},{"key":"2023120108101139000_64.12.1918.18","first-page":"2567","article-title":"Preclinical evaluation of a novel radioligand therapy for patients with prostate cancer: biodistribution and efficacy of 177Lu-rhPSMA-10.1 in comparison with 177Lu-PSMA-I&T","volume":"63","author":"Foxton","year":"2022","journal-title":"J Nucl Med"},{"key":"2023120108101139000_64.12.1918.19","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med."},{"key":"2023120108101139000_64.12.1918.20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","article-title":"IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms","volume":"7","author":"Andersson","year":"2017","journal-title":"EJNMMI Res."},{"key":"2023120108101139000_64.12.1918.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.icrp.2007.10.003]"},{"key":"2023120108101139000_64.12.1918.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.zemedi.2015.01.001"},{"key":"2023120108101139000_64.12.1918.23","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023120108101139000_64.12.1918.24","doi-asserted-by":"crossref","first-page":"S673","DOI":"10.1016\/j.annonc.2021.08.1160","article-title":"647TiP PSMAddition: a phase III trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer [abstract]","volume":"32","author":"Tagawa","year":"2021","journal-title":"Ann Oncol."},{"key":"2023120108101139000_64.12.1918.25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy-like picture","volume":"83","author":"Sch\u00e4fer","year":"2023","journal-title":"Eur Urol."},{"key":"2023120108101139000_64.12.1918.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0778-1"},{"key":"2023120108101139000_64.12.1918.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.214379"},{"key":"2023120108101139000_64.12.1918.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.02.2969"},{"key":"2023120108101139000_64.12.1918.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203539"},{"key":"2023120108101139000_64.12.1918.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:12:58Z","timestamp":1701447178000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.2967\/jnumed.123.265970"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265970","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}